Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

ClinicalTrials.gov ID: NCT00439725

Public ClinicalTrials.gov record NCT00439725. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study

Study identification

NCT ID: NCT00439725
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 1,197 participants

Conditions and interventions

Conditions

Venous Thromboembolism

Interventions

Rivaroxaban (Xarelto, BAY59-7939) Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2007
Primary completion: Jul 31, 2009
Completion: Aug 31, 2009
Last update posted: Nov 3, 2014

2007 – 2009

United States locations

U.S. sites: 25
U.S. states: 17
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72205	—
Not listed	Los Angeles	California	90095	—
Not listed	Redlands	California	92373	—
Not listed	Bay Pines	Florida	33744	—
Not listed	Melbourne	Florida	32901	—
Not listed	Miami	Florida	33136-1096	—
Not listed	Miami	Florida	33136	—
Not listed	Decatur	Georgia	30033	—
Not listed	Idaho Falls	Idaho	83404	—
Not listed	Covington	Louisiana	70433	—
Not listed	Baltimore	Maryland	21215-5271	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Albuquerque	New Mexico	87108	—
Not listed	Chapel Hill	North Carolina	27599-7035	—
Not listed	Greensboro	North Carolina	27401	—
Not listed	Greensboro	North Carolina	27403	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Pittsburgh	Pennsylvania	15224	—
Not listed	Corsicana	Texas	75110	—
Not listed	San Antonio	Texas	78229	—
Not listed	Murray	Utah	84107	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Burlington	Vermont	05401	—
Not listed	Fredericksburg	Virginia	22401	—
Not listed	Spokane	Washington	99204	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 297 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00439725, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 3, 2014 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00439725 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →